On March 18, Eyebright Medical—an industry leader in ophthalmic medical devices—was invited to attend the Seventh First Member Representatives Conference and the Seventh First Board of Directors Conference, together with the Policy Annual Conference, organized by the China Medical Device Industry Association. Senior officials from relevant government departments provided in-depth guidance on the latest policy directions and industry trends to help the sector seize opportunities under the “15th Five-Year Plan” and advance high-quality development. The Conference also completed leadership re-election, with Dr. Xie Jiangbing, Chairman and General Manager of Eyebright Medical, elected as Vice Chairman. 

With 16 years of focus on ophthalmology, Eyebright Medical continues to drive innovation through its core technology platforms, launching products across three major segments surgery treatment, myopia management, and customer vision care. The company has successively launched multiple products that address domestic market gaps and break long-standing international monopolies.

By leveraging its technological and platform strengths, Aibot Medical continues to invest in an R&D pipeline of innovative, high-growth products, helping to improve public health. As an industry leader, the company actively supports academic exchange domestically and internationally, participates in the development of industry standards, and runs public-welfare talent programs to promote sustainable progress. Looking ahead, Aibot Medical will capitalize on national initiatives supporting high-end medical equipment, partner with industry peers, and explore new avenues for growth to build a stronger future for the sector.